TX-FORTERRO
17.2.2021 10:02:16 CET | Business Wire | Press release
Forterro , a group of companies that deliver enterprise resource planning (ERP) software to small- and medium-sized businesses, today announced the appointment of two new executives to lead the company into a new phase of growth in its core market, Europe.
Dean Forbes, a longtime, U.K.-based software executive who was most recently the president of The Access Group, was named Forterro’s chief executive. Paul Smolinski, the former chief financial officer of HR and payroll software firm CoreHR, was named CFO. The two U.K.-based leaders have been tapped to continue Forterro’s growth strategy in Europe, working with the company’s strategic leadership teams across the group’s primary business units in France, Germany, Poland, Sweden, and Switzerland.
Forbes joins Forterro after an extensive career in executive and senior leadership roles for a number of international software companies. Most recently he led the growth and expansion of CoreHR, a UK HCM software provider, across Europe. CoreHR was acquired by The Access Group, where Forbes subsequently served as president and executive board member. Prior to CoreHR, Forbes was CEO of Paris-headquartered SaaS software company KDS, where he led the successful growth and international expansion of the firm, leading to its acquisition by American Express. Earlier in his career, Forbes held senior leadership roles at Philadelphia HQ’d Primavera Systems and, subsequently, Oracle where he was global vice president for sales and marketing for the PPM Division. Forbes brings this wealth of experience to Forterro and its acquired companies, which include abas Software (Germany); BPSC (Poland); Clip Industrie, Silog and Sylob (France); Jeeves and Infocube (Sweden); and ProConcept (Switzerland). Forterro is backed by global, technology-focused investment firm Battery Ventures.
“I am thrilled to become part of such a strong group of ERP companies, who are all successfully operating in one of the strongest, most steadily growing markets in enterprise software,” Forbes said. “The cornerstone of our ongoing success will be to continue investing in the market leadership positions of local and niche ERP software businesses throughout Europe. I am excited about leading the next stage of the Forterro journey as we look to continue to grow the business aggressively, both organically and through further acquisitions.”
“Bringing in new, Europe-based leadership is part of the natural evolution of Forterro,” said Dave Tabors, a Forterro board member and Battery Ventures private equity partner. “Former CEO Jeff Tognoni, former COO Scott Malia, and the rest of the U.S.-based Forterro leadership team have done an outstanding job of growing the business by evaluating, acquiring, and operating ERP companies. To push Forterro into its next stage of development, however, it is time to cultivate leadership talent in closer proximity to our business unit operations. We are very excited to work with Dean as he prepares Forterro for its next stage of growth.”
“We have spent the last several years working closely with our counterparts in Europe to build sustainable growth strategies and unique operating approaches for each business unit and product market,” added Jeff Tognoni, who is stepping down after leading Forterro and growing revenue more than seven-fold since the initial acquisition of Jeeves Information Systems in 2012. “The strength of our local teams and their businesses lets me know that part of our job is done, and that Forterro is ready for new challenges and continued success under the leadership of Dean and Paul.”
ABOUT FORTERRO
Forterro is a group of companies that deliver ERP software to SMEs in specialized geographical or vertical markets. Backed by the investment of Battery Ventures , Forterro operates business units in Sweden, Switzerland, France, Poland, and Germany, as well as regional office locations and research and development centers around the world. Through its ever-growing ecosystem of IP and capital, Forterro collaborates with local management teams to strengthen the solution offerings and operational performance of its portfolio companies. For more information, visit www.forterro.com .
ABOUT BATTERY VENTURES
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom